Practice of ovarian stimulation among poor responders in a country with limited resources: case of the Paul and Chantal Biya human reproduction center, Yaoundé, Cameroon

Ngono Akam Marga Vanina; Belinga Etienne; Mpono Pascale; Nyada Serge Robert; Christiane Nsahlaie; Mendoua Michele; Kasia Jean Marie

doi:10.18203/2320-1770.ijrcog20233619

Authors

Ngono Akam Marga Vanina Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Gynecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Essos Hospital Center Cameroon Yaoundé, Cameroon
Belinga Etienne Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Gynecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Essos Hospital Center Cameroon Yaoundé, Cameroon
Mpono Pascale Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Gynecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Essos Hospital Center Cameroon Yaoundé, Cameroon
Nyada Serge Robert Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Gynecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Essos Hospital Center Cameroon Yaoundé, Cameroon
Christiane Nsahlaie Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Essos Hospital Center Cameroon Yaoundé, Cameroon
Mendoua Michele Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon
Kasia Jean Marie Department of Obstetrics and Gynecology, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Essos Hospital Center Cameroon Yaoundé, Cameroon; Gynecological Endoscopic Surgery and Human Reproductive Teaching Hospital, Essos Hospital Center Cameroon Yaoundé, Cameroon

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20233619

Keywords:

CHRACERH/Yaoundé, IVF/ICSI, Ovarian stimulation, Poor responders

Abstract

Background: Approximatively 2 to 30% of women who undergo ovarian stimulation have a poor response. The management is not clearly defined, constituting a challenge for clinicians and biologist.

Methods: This was a longitudinal descriptive study with prospective data collection that took place at Paul and Chantal Biya Gynecological Endoscopic surgery and Human Reproductive Teaching Center, during a period of 1 year and 6 months, from June 2020 to November 2021. Our objective was to describe the practice of ovarian stimulation of patients judged to be poor responders in CHRACERH. We highlighted the numbers, percentages, averages and their standard deviations. Statistical analyzes were carried out using SPSS v15.0 software.

Results: Out of 159 cycles included, we identified 55 patients considered possible poor responders, i.e. a prevalence of 34.6%; the average age was 36.36±6.2 years with extremes ranging from 33 to 44 years, mainly overweight in 81.8% of cases. The average AMH level was 0.9±0.4 ng/ml, the average CFA 6.15±3.7. 87.3% of patients were on their first stimulation attempt, the long-delay agonist protocol and the short agonist protocol were used in 58.2% and 41.8% respectively. The maximum daily dose in patients was 300 IU with an average total dose of gonadotropin used of 3371.8±874 IU. At the end of the ovarian stimulation, the average number of follicles collected and mature oocytes were respectively 5.6±3.6 and 4±2.9 with an average maturity rate of 70.7±31% as well as an average fertilization rate in ICSI of 45.2±32%. The pregnancy rate was 12% among poor responders.

Conclusions: Poor responders constitute a large proportion of patients stimulated at CHRACERH; their still low pregnancy rates prompt an improvement in care.

Metrics

Metrics Loading ...

References

Patrizio P, Vaiarelli A, Levi Setti PE, Tobler K, Shoham G, Leong M, et al. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reprod Biomed Online. 2015;30(6):581-92.

Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril. 2011;96(5):1058-61.

Ferraretti AP, Marca AL, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of ‘‘poor response’’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-24.

Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod Oxf Engl. 2014;29(9):1842‑5.

Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560-79.

Dremirol A, Gurgan T. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. Fertil Steril. 2009;92:481-5.

Merviel P, Cabry-Goubet R, Lourdel E, Devaux A, Belhadri-Mansouri N, Copin H, et al. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy. Reprod Health. 2015;12: 52.

ESHRE Reproductive endocrinology Guidelines group Guidelines, October 2019.

Anahory T, Ranisavljevic N, Bringer-Deutsch S. Poor responders: How could we improve our results? Gynecol Obstet Fertil Senol. 2017;45(2):95-103.

Farquhar C, Rombauts L, Kremer JA, Lethaby A, Ayeleke RO. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev. 2017;5:Cd006109.

Nejad ES, Ghaleh FB, Eslami B, Haghollahi F, Bagheri M, Masoumi M. Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: An RCT. Int J Reprod BioMed. 2018;16(8):535.

Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97:561-71.

Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of ‘low prognosis patients in assisted reproductive technology’ and its proposed marker of successful outcome. F1000Res. 2016;5:2911.

Bassiouny YA, Dakhly DM, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil Steril. 2016;105(3):697-702.

Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015;11:Cd009749.

Bosdou JK, Venetis CA, Dafopoulos K, Zepiridis L, Chatzimeletiou K, Anifandis G, et al. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum Reprod. 2016;31:977-85.

Kim CH, Ahn JW, Moon JW, Kim SH, Chae HD, Kang BM. Ovarian features after 2 weeks, 3 weeks and 4 weeks transdermal testosterone gel treatment and their associated effect on IVF outcomes in poor responders. Develop Reprod. 2014;18:145-52.

Revelli A, Dolfin E, Gennarelli G, Lantieri T, Massobrio M, Holte JG, et al. Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study. Fertil Steril. 2008;90(5):1685-91.

Caprio F, D’Eufemia MD, Trotta C, Campitiello MR, Ianniello R, Mele D, et al. Myo-inositol therapy for poor responders during IVF: a prospective controlled observational trial. J Ovar Res. 2015;8:37.